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CASE REPORT
In December 2010, a 66-year-old woman was diag-
nosed with an American Joint Committee on Cancer stage 
IIIB (T4 N1 M0) squamous carcinoma of the lung. She 
received three cycles of neoadjuvant treatment with cis-
platin and gemcitabine. Radiological reevaluation showed 
thoracic disease progression and liver relapse, which 
was histologically confirmed in May 2011. She there-
fore received second-line therapy with docetaxel without 
benefit; despite shrinkage of the primary tumor the liver 
metastases progressed and new gastric and peritoneal 
lesions were observed in August 2011. Histology proved 
gastric lesions to be metastases of primitive squamous car-
cinoma of the lung. Malignant ascites necessitated several 
paracenteses. The patient was enrolled in a translational 
research program for the characterization of dissemi-
nated tumor cells (DTC) in solid tumors, and tumor cells 
obtained from the ascites were successfully cultured and 
passaged as previously described.1 A third-line treatment 
with vinorelbine was initiated, but the patient’s condition 
rapidly deteriorated and she died of respiratory failure sev-
eral weeks later.
Genetic analysis was performed on laser-microdis-
sected paraffin-embedded tissue of the primary tumor, of 
liver and gastric metastases, and on the cell line established 
from DTC of the ascites. Single-cell analysis of three dif-
ferent DTC was also performed. Mutational status of the 
genes BRAF (codon 600), NRAS (codons 12, 13, and 61), 
KRAS (codons 12, 13, and 61) was assessed both by reverse-
transcriptase polymerase chain reaction and melting curve 
analysis, as well as by direct sequencing as further control. 
Results are listed in Table 1.
The cell line established from DTC of an ascites speci-
men was heterozygotic with respect to NRAS codon 12 with 
a c.35G>A (p. G12D) mutation (MT). Single-cell analysis 
 performed on three individual DTC from the ascites-derived 
cell line, however, showed homozygotic c.35G>A MT in 
two cells and homozygotic wild-type (WT) in one cell, 
indicating that actually at least two different cancer clones 
coexisted in the cell line. Genotyping of NRAS codon 12 
at the tissue level of the primary tumor showed c.35G>A 
MT, the liver metastasis heterozygotic with c.35G>A MT 
and the gastric metastasis WT. Sequencing matched with 
the polymerase chain reaction results. NRAS mutational 
status corresponded to distinctive histological characteris-
tics (Fig. 1).
Discordant genetic patterns between different com-
partments have been reported in several tumor entities 
also by our own group.2 However, in this case, because it 
is unlikely that a WT allele suddenly reappeared during the 
metastatic process, we must postulate heterogeneity of the 
primary tumor concerning NRAS codon 12.3 Initial diag-
nosis of the T4 primary tumor was achieved by bronchos-
copy, which might have missed the area enriched in WT 
forms. Nonetheless, two different tumor clones were clearly 
detected at DTC level. Peritoneal involvement was con-
temporary to the gastric metastasis, which on the contrary 
was WT and succeeded the liver metastasis, which showed 
heterogeneity with regard to NRAS codon 12. Histology 
seemed to exclude a mixture of primaries. On the basis of 
these observations, we have to assume that the two differ-
ent clones evolved in parallel without positive selection 
of one clone over the other because they appeared within 
the same metastatic foci. The most likely explanation of 
our results is that two genetically distinct subclones of the 
primary seeded metastases with similar homing patterns. 
Intratumoral metastatic heterogeneity as evolution of the 
metastatic clone is an accepted concept. Nonetheless, to the 
best of our knowledge, our results indicated for the first time 
that metastasis seeding might not be monoclonal in contrast 
to common beliefs and recent findings.4,5 Our observation 
may be of relevance for targeted therapies directed against 
single MTs. Furthermore, disseminated tumor cells in body 
fluids and peripheral blood may mirror the tumor composi-
tion at the tissue level.
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FIGURE 1.  Histology of the tumor: (A), primary pulmonary carcinoma (hematoxylin and eosin staining); (B), liver metastasis 
with extensive necrosis (hematoxylin and eosin staining); (C), gastric metastasis. The primary pulmonary carcinoma exhibited 
histomorphological features of a squamous carcinoma with keratinization (A). The liver metastasis showed an increased nuclear 
polymorphism with bizarre nuclei accompanied by extensive necrotic areas. The squamous differentiation was still visible with 
several keratin pearls (B). The metastasis in the stomach exhibited features of a squamous carcinoma without signs of keratiniza-
tion (C). The nuclear polymorphism is similar to the one observed in the primary tumor.
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TABLE 1. Mutational Status of BRAF, NRAS, and KRAS in Tissues, DTC-Derived Cell Line and in Single DTC
Time Tissue
Genotypic Analysis
BRAF 
Codon 600
NRAS 
Codon 12
NRAS 
Codon 13
NRAS 
Codon 61
KRAS 
Codon 12
KRAS 
Codon 13
KRAS 
Codon 61
12/2010 Primary tumor WT MT WT WT WT WT WT
05/2011 Liver metastasis WT HT WT WT WT WT WT
08/2011 Gastric metastasis WT WT WT WT WT WT WT
08/2011 DTC-derived cell line WT HT WT WT WT WT WT
08/2011 DTC # 1 WT MT WT WT WT WT WT
08/2011 DTC # 2 WT MT WT WT WT WT WT
08/2011 DTC # 3 WT WT WT WT WT WT WT
WT, wild-type; MT, mutated; HT, heterozygotic; DTC, disseminated tumor cells.
